

**PRESS RELEASE****Oasmia presents Phase III results for Paclical® Vet in Copenhagen**

The company Oasmia Pharmaceutical will present the first results from a Phase III-study with the drug candidate Paclical® Vet at a veterinary congress in Copenhagen. The top veterinary oncologists in the USA and Europe will attend the congress.

Oasmia has performed a Phase III-study with the drug candidate Paclical® Vet on dogs with mastocytoma grade II-III during 2007-2008. The company will present the first results at the congress ESVONC and VCS joint meeting in Copenhagen during February 28 to March 1 2008. The company is main sponsor for the congress.

ESVONC (European Society of Veterinary Oncology) is an association of the most prominent veterinary oncologists in Europe. VCS (Veterinary Cancer Society) is the ESVONC's American counterpart. The congress is the first that these two organizations are holding together.

- It is incredibly exciting that Oasmia has chosen to present Phase III-data at the first world congress for cancer in animals concerning the first cytostatic planned to be registered for veterinary use, says Annemarie T. Kristensen, professor of oncology, Institute for Small Animal Diseases, Copenhagen University.

- It is very important that we can present the first Phase III-results at this key event and we are delighted to support this congress as one of the main sponsors, says Oasmia CEO Julian Aleksov in a comment.

The participation and presentation will open many new collaboration opportunities for Oasmia's veterinary medicine operations as the drug candidate now is a lot closer to registration in Europe and the USA.

---

More information is available at [www.ngm.se](http://www.ngm.se) or [www.oasmia.com](http://www.oasmia.com)

For further information please contact: [info@oasmia.com](mailto:info@oasmia.com) or call: +46 (0) 18 50 54 40

*Oasmia Pharmaceutical AB is a pharmaceutical company that specialises in the treatment of severe diseases. A pharmaceutical company based on the latest concepts in bio-organic chemistry. The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase. Oasmia is listed on NGM Equity.*